Omeros and Novo Nordisk Close $2.1B Agreement for Phase 2 Drug Zaltenibart

Omeros (OMER) announced the closing of a major asset purchase and licensing agreement with Novo Nordisk (NVO) for zaltenibart, a phase 2 biologic targeting MASP-3 for treating rare blood and kidney disorders.

Deal Structure and Financial Terms

Total value: Up to $2.1 billion
Upfront + near-term payments: $340 million
Upfront paid at closing: $240 million
Milestone payments: Up to the full $2.1B based on clinical, regulatory, and commercial milestones
Royalties: Tiered royalties on potential future global net sales

The deal was originally announced in October and has now been formally completed.

Zaltenibart: A Phase 2 MASP-3 Biologic for Rare Disorders

Zaltenibart is designed to inhibit MASP-3, a key component of the complement system involved in certain rare hematologic and renal diseases.
Novo Nordisk is expected to advance the program into later-stage clinical development.

Potential Therapeutic Areas

Rare blood disorders
Complement-related kidney diseases
Broader immunology and inflammation applications

Omeros Retains Rights to Its Small-Molecule MASP-3 Program

A key element of the agreement is that Omeros retains its MASP-3 small-molecule program, which is independent of zaltenibart.

Omeros’ Remaining Pipeline Strength

Maintains ownership of complementary small-molecule assets
Potential for future partnerships or internal development
Continues strategic focus on rare-disease therapeutics